Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-CDKN2A Recombinant Antibody (CBFYC-1637) (CBMAB-C1698-FY)


See all CDKN2A antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human, Mouse, Rat
Clone
CBFYC-1637
Antibody Isotype
IgG2a, κ
Application
WB, IP, IF, IHC-P, ELISA

Basic Information

Immunogen
Amino acids 1-168 representing full length p16 INK4A of mouse.
Host Species
Mouse
Specificity
Human, Mouse, Rat
Antibody Isotype
IgG2a, κ
Clonality
Monoclonal Antibody
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.
ApplicationNote
WB1:100-1:1,000
IP1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
IF(ICC)1:50-1:500
IHC-P1:50-1:500
ELISA1:100-1:1,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, 0.1% gelatin
Preservative
< 0.1% sodium azide
Concentration
0.2 mg/ml
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at-20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Cyclin Dependent Kinase Inhibitor 2A
Introduction
Thus some aberration of the CDKN2A, CDK4 and RB1 genes appears to be almost obligatory in glioblastomas.
Entrez Gene ID
1029
UniProt ID
P42771
Alternative Names
Cyclin Dependent Kinase Inhibitor 2A; Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4); Cyclin-Dependent Kinase 4 Inhibitor A; Cyclin-Dependent Kinase Inhibitor 2A; Multiple Tumor Suppressor 1; Alternative Reading Frame; P16-INK4A; P16INK4A; P14ARF; CDKN2; CDK4I; MTS-1; MTS1; MLM
Function
Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.
Biological Process
Cell cycle arrest Source: BHF-UCL
Cellular senescence Source: BHF-UCL
G1/S transition of mitotic cell cycle Source: BHF-UCL
Negative regulation of cell growth Source: BHF-UCL
Negative regulation of cell-matrix adhesion Source: BHF-UCL
Negative regulation of cell population proliferation Source: BHF-UCL
Negative regulation of cyclin-dependent protein serine/threonine kinase activity Source: BHF-UCL
Negative regulation of G1/S transition of mitotic cell cycle Source: Reactome
Negative regulation of NF-kappaB transcription factor activity Source: BHF-UCL
Negative regulation of phosphorylation Source: BHF-UCL
Negative regulation of transcription, DNA-templated Source: UniProtKB
Positive regulation of cellular senescence Source: UniProtKB
Positive regulation of macrophage apoptotic process Source: BHF-UCL
Positive regulation of smooth muscle cell apoptotic process Source: BHF-UCL
Ras protein signal transduction Source: BHF-UCL
Regulation of transcription initiation from RNA polymerase II promoter Source: Reactome
Replicative senescence Source: BHF-UCL
Senescence-associated heterochromatin focus assembly Source: UniProtKB
Cellular Location
Nucleus; Cytoplasm
Involvement in disease
The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients.
Melanoma, cutaneous malignant 2 (CMM2): A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC): An inherited cancer predisposition syndrome characterized by an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer.
Melanoma-astrocytoma syndrome (MASTS): Characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.
PTM
Phosphorylation seems to increase interaction with CDK4.
More Infomation

Xu, J., Li, N., Deng, W., & Luo, S. (2021). Discovering the mechanism and involvement of the methylation of cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and its special locus region in gastric cancer. Bioengineered, 12(1), 1286-1298.

Salmani, T., Ghaderian, S. M. H., Hajiesmaeili, M., Mirghaed, O. R., Rakhshan, A., Nasiri, M. J., & Mohammadi, M. (2020). Cyclin dependent kinase inhibitor 2A and miR-671-5p expression profile in Iranian glioblastoma multiforme. Gene Reports, 19, 100620.

Althakfi, W., Gazzo, S., Blanchet, M., Isaac, S., Piaton, E., Villeneuve, L., ... & Brevet, M. (2020). The value of BRCA‐1‐associated protein 1 expression and cyclin‐dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens. Cytopathology, 31(1), 5-11.

Seifi, S., Pouya, F., Rahmani, M., Mehramiz, M., Rastgar‐Moghadam, A., Gharib, M., ... & Avan, A. (2020). Association of cyclin‐dependent kinase inhibitor 2A/B with increased risk of developing breast cancer. Journal of cellular physiology, 235(6), 5141-5145.

Zhang, H. H., Mao, J. S., & Hu, W. F. (2019). Functional genetic single-nucleotide polymorphisms (SNPs) in cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) locus are associated with risk and prognosis of osteosarcoma in chinese populations. Medical science monitor: international medical journal of experimental and clinical research, 25, 1307.

Zhang, W., Kuang, P., & Liu, T. (2019). Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Annals of medicine, 51(1), 28-40.

Agarwal, M., Bakhshi, S., Dwivedi, S. N., Kabra, M., Shukla, R., & Seth, R. (2018). Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia. Pediatric blood & cancer, 65(6), e27001.

O'Hara, S. P., Splinter, P. L., Trussoni, C. E., Pisarello, M. J. L., Loarca, L., Splinter, N. S., ... & LaRusso, N. F. (2017). ETS proto-oncogene 1 transcriptionally up-regulates the cholangiocyte senescence-associated protein cyclin-dependent kinase inhibitor 2A. Journal of Biological Chemistry, 292(12), 4833-4846.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CDKN2A Recombinant Antibody (CBFYC-1637)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry